Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Tissue Renewal without Stem Cells01:23

Tissue Renewal without Stem Cells

1.8K
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
1.8K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

24.4K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
24.4K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective Analysis.

Diabetes care·2026
Same author

Insulin Costs and Use by Medicare Beneficiaries After the Inflation Reduction Act Out-of-Pocket Cap.

JAMA·2026
Same author

Factors Associated With Nocturnal Hypoglycemia After Exercise in the Type 1 Diabetes and Exercise Initiative (T1DEXI) Study.

Diabetes care·2026
Same author

Challenges in and opportunities for individualising diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.

Diabetologia·2026
Same author

Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.

Diabetes care·2026
Same author

Interoceptive Awareness Moderates the Relationship Between Hypoglycemia Exposure and Symptom Recognition in Adults With Type 1 Diabetes.

Diabetes care·2025

相关实验视频

Updated: Sep 18, 2025

Differentiation of Human Pluripotent Stem Cells into Insulin-Producing Islet Clusters
08:41

Differentiation of Human Pluripotent Stem Cells into Insulin-Producing Islet Clusters

Published on: June 23, 2023

3.3K

1型糖尿病的干细胞衍生,完全分化的岛屿.

Trevor W Reichman1, James F Markmann2, Jon Odorico3

  • 1Toronto General Hospital, University Health Network, University of Toronto, Toronto.

The New England journal of medicine
|June 22, 2025
PubMed
概括

新型干细胞疗法Zimislecel在恢复1型糖尿病患者的小岛功能方面表现有前途. 早期的结果表明改善了葡萄糖控制和胰岛素独立性,需要进一步研究.

更多相关视频

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
10:12

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System

Published on: December 16, 2021

2.9K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

1.9K

相关实验视频

Last Updated: Sep 18, 2025

Differentiation of Human Pluripotent Stem Cells into Insulin-Producing Islet Clusters
08:41

Differentiation of Human Pluripotent Stem Cells into Insulin-Producing Islet Clusters

Published on: June 23, 2023

3.3K
Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
10:12

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System

Published on: December 16, 2021

2.9K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

1.9K

科学领域:

  • 再生医学是一种再生医学.
  • 内分泌学 在内分泌学.
  • 免疫学 免疫学 免疫学

背景情况:

  • 1型糖尿病 (T1D) 是一种自身免疫性疾病,其特征是破坏产生胰岛素的β细胞.
  • 目前的管理依赖于外源性胰岛素,在实现最佳血糖控制和预防并发症方面存在局限性.
  • 异性干细胞衍生小岛细胞疗法为恢复内源性胰岛素生产提供了一个潜在的替代方案.

研究的目的:

  • 评估zimislecel在1型糖尿病患者中的安全性和有效性.
  • 评估zimislecel在恢复生理小岛功能和改善血糖控制方面的潜力.

主要方法:

  • 一个涉及1型糖尿病参与者的1-2期临床试验.
  • 齐米斯莱塞尔 (半剂量或全剂量) 通过门静脉输液给药.
  • 参与者接受了无葡萄糖皮质激素的免疫抑制疗法.
  • 主要终点包括安全性,免于严重低血糖症和糖化血红蛋白水平.
  • 二级终点包括胰岛素独立性和通过C-检测评估小岛功能.

主要成果:

  • 所有参与者都显示了输液后植入和小岛功能的证据,可检测的C-水平表明了这一点.
  • 全剂量组中的大多数参与者实现了严重低血糖的自由,并保持了糖化血红蛋白低于7%的水平.
  • 全剂量组中的83%的参与者在第365天实现了胰岛素独立.
  • 中性是最常见的严重不良事件;发生了两起死亡,与研究药物无关.

结论:

  • 齐米斯莱塞尔在1型糖尿病患者中恢复生理小岛功能方面表现出潜力.
  • 这些发现支持继续对齐米斯莱塞尔作为T1D治疗选择的临床研究.
  • 需要进一步的研究来证实这些初步结果在更大,长期的研究中.